Hanyang Med Rev.  2018 Mar;38(1):38-48. 10.7599/hmr.2018.38.1.38.

Patient Blood Management: An Internist's Perspective

• Uhm J

• KMID: 2407800
• DOI: http://doi.org/10.7599/hmr.2018.38.1.38

Abstract

Patient blood management (PBM) is an evidence-based, patient-focused approach to optimize the management of patient and blood transfusion. While PBM is relatively well established in perioperative care, it is not as well established in the medical field. Since anemia in medical patients is heterogeneous and complex in its pathogenesis, the evidence for the threshold of hemoglobin for red blood cell (RBC) transfusion and the use of erythropoiesis-stimulating agents (ESAs) is not strong. While anemia seems to be an adverse risk factor for mortality, it is uncertain if rapid correction of anemia through RBC transfusion can reverse the negative impact of anemia on clinical outcomes. The introduction of ESA is a breakthrough in reducing RBC transfusion and managing anemic patients with renal disease and cancer. Despite promising results from early trials, the United States Food and Drug Administration issued a black box warning for ESAs in 2007 because of concerns about higher mortality, serious cardiovascular and thromboembolic events, and tumor progression. Therefore, the individualized approach to each patient with anemia is recommended in various medical conditions such as acute coronary syndrome, heart failure, chronic kidney disease, and malignancies.

Keyword

Transfusion; Iron; Erythropoietin; Chemotherapy-induced anemia; Anemia of renal disease

MeSH Terms

Acute Coronary Syndrome
Anemia
Blood Transfusion
Drug Labeling
Erythrocytes
Erythropoietin
Heart Failure
Humans
Iron
Mortality
Perioperative Care
Renal Insufficiency, Chronic
Risk Factors
United States Food and Drug Administration
Erythropoietin
Iron

Reference

1. WHO/BTS. Concept Paper. Global forum for blood safety: patient blood management. Dubai, United Arab Emirates: World Health Organization;2011.

2. Shander A, Isbister J, Gombotz H. Patient blood management: the global view. Transfusion. 2016; 56:Suppl 1. S94–S102.

3. Hofmann A, Farmer S, Shander A. Five drivers shifting the paradigm from product-focused transfusion practice to patient blood management. Oncologist. 2011; 16:Suppl 3. 3–11.

4. Gross I, Trentino KM, Andreescu A, Pierson R, Maietta RA, Farmer S. Impact of a patient blood management program and an outpatient anemia management protocol on red cell transfusions in oncology inpatients and outpatients. Oncologist. 2016; 21:327–332.

5. Tinegate H, Chattree S, Iqbal A, Plews D, Whitehead J, Wallis JP, et al. Ten-year pattern of red blood cell use in the North of England. Transfusion. 2013; 53:483–489.

6. Kim V, Kim H, Lee K, Chang S, Hur M, Kang J, et al. Variation in the numbers of red blood cell units transfused at different medical institution types from 2006 to 2010 in Korea. Ann Lab Med. 2013; 33:331–342.

7. Wells AW, Llewelyn CA, Casbard A, Johnson AJ, Amin M, Ballard S, et al. The EASTR Study: indications for transfusion and estimates of transfusion recipient numbers in hospitals supplied by the National Blood Service. Transfus Med. 2009; 19:315–328.

8. Wells AW, Mounter PJ, Chapman CE, Stainsby D, Wallis JP. Where does blood go? Prospective observational study of red cell transfusion in north England. BMJ. 2002; 325:803.

9. Services USDoHaH. The 2011 National Blood Collection and Utilization Survey Report. 2011.

10. Hoffmann A, Friedman D, Farmer S. Western Australian Patient Blood Management Project 2008–2012: Analysis, Strategy, Implementation and Financial Projections. Health WADo. Perth: 2007. p. 1–154.

11. Patel KV. Epidemiology of anemia in older adults. Semin Hematol. 2008; 45:210–217.

12. Aapro M, Osterborg A, Gascon P, Ludwig H, Beguin Y. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol. 2012; 23:1954–1962.

13. Kasper D, Fauci A, Hauser S, Longo D, Jameson JL, Loscalzo J. Harrion's principles of intermal medicine. 19 ed. McGraw-Hill Education;2015.

14. Authority TNB. Patient blood management guidelines: modeul 3-medical. Council NHaMR. Canbera, Australia: 2012.

15. Farhan S, Baber U, Mehran R. Anemia and Acute Coronary Syndrome: Time for Intervention Studies. J Am Heart Assoc. 2016; 5.

16. Anker SD, Voors A, Okonko D, Clark AL, James MK, von Haehling S, et al. Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. Eur Heart J. 2009; 30:1331–1339.

17. Valeur N, Nielsen OW, McMurray JJ, Torp-Pedersen C, Kober L, Group TS. Anaemia is an independent predictor of mortality in patients with left ventricular systolic dysfunction following acute myocardial infarction. Eur J Heart Fail. 2006; 8:577–584.

18. Mamas MA, Kwok CS, Kontopantelis E, Fryer AA, Buchan I, Bachmann MO, et al. Relationship between anemia and mortality outcomes in a national acute coronary syndrome cohort: insights from the uk myocardial ischemia national audit project registry. J Am Heart Assoc. 2016; 5.

19. Adams KF Jr, Pina IL, Ghali JK, Wagoner LE, Dunlap SH, Schwartz TA, et al. Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure. Am Heart J. 2009; 158:965–971.

20. Gilreath JA, Stenehjem DD, Rodgers GM. Diagnosis and treatment of cancer-related anemia. Am J Hematol. 2014; 89:203–212.

21. Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess. 2007; 11:1–202. iii–iv.

22. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001; 61:2911–2916.

23. Spivak JL, Gascon P, Ludwig H. Anemia management in oncology and hematology. Oncologist. 2009; 14:Suppl 1. 43–56.

24. Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist. 2008; 13:Suppl 3. 21–26.

25. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004; 116:Suppl 7A. 11S–26S.

26. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004; 40:2293–2306.

27. Volkova N, Arab L. Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis. 2006; 47:24–36.

28. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant. 2003; 18:353–361.

29. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339:584–590.

30. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000; 58:1325–1335.

31. Carless PA, Henry DA, Carson JL, Hebert PP, McClelland B, Ker K. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2010; CD002042.

32. Carson JL, Stanworth SJ, Roubinian N, Fergusson DA, Triulzi D, Doree C, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2016; 10:CD002042.

33. Cooper HA, Rao SV, Greenberg MD, Rumsey MP, McKenzie M, Alcorn KW, et al. Conservative versus liberal red cell transfusion in acute myocardial infarction (the CRIT Randomized Pilot Study). Am J Cardiol. 2011; 108:1108–1111.

34. Carson JL, Brooks MM, Abbott JD, Chaitman B, Kelsey SF, Triulzi DJ, et al. Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J. 2013; 165:964–971.e1.

35. Alexander KP, Chen AY, Wang TY, Rao SV, Newby LK, LaPointe NM, et al. Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2008; 155:1047–1053.

36. Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, McCabe CH, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation. 2005; 111:2042–2049.

37. Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholz HM. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med. 2001; 345:1230–1236.

38. Chatterjee S, Wetterslev J, Sharma A, Lichstein E, Mukherjee D. Association of blood transfusion with increased mortality in myocardial infarction: a meta-analysis and diversity-adjusted study sequential analysis. JAMA Intern Med. 2013; 173:132–139.

39. Garfinkle M, Lawler PR, Filion KB, Eisenberg MJ. Red blood cell transfusion and mortality among patients hospitalized for acute coronary syndromes: a systematic review. Int J Cardiol. 2013; 164:151–157.

40. Carson JL, Grossman BJ, Kleinman S, Tinmouth AT, Marques MB, Fung MK, et al. Red blood cell transfusion: a clinical practice guideline from the AABB^*. Ann Intern Med. 2012; 157:49–58.

41. Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, et al. Clinical practice guidelines From the AABB: red blood cell transfusion thresholds and storage. JAMA. 2016; 316:2025–2035.

42. Network NCC. NCCN Guidelines Version 1.2018. Cancer- and Chemotherapy-Induced Anemia. 2018.

43. Kader AS, Lim JT, Berthelet E, Petersen R, Ludgate D, Truong PT. Prognostic significance of blood transfusions in patients with esophageal cancer treated with combined chemoradiotherapy. Am J Clin Oncol. 2007; 30:492–497.

44. Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999; 86:1528–1536.

45. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008; 168:2377–2381.

46. DeZern AE, Williams K, Zahurak M, Hand W, Stephens RS, King KE, et al. Red blood cell transfusion triggers in acute leukemia: a randomized pilot study. Transfusion. 2016; 56:1750–1757.

47. Webert KE, Cook RJ, Couban S, Carruthers J, Lee KA, Blajchman MA, et al. A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion. 2008; 48:81–91.

48. Blajchman MA, Bordin JO, Bardossy L, Heddle NM. The contribution of the haematocrit to thrombocytopenic bleeding in experimental animals. Br J Haematol. 1994; 86:347–350.

49. Malik J, Kim AR, Tyre KA, Cherukuri AR, Palis J. Erythropoietin critically regulates the terminal maturation of murine and human primitive erythroblasts. Haematologica. 2013; 98:1778–1787.

50. Nakamura R, Takahashi A, Yamada T, Miyai N, Irie H, Kinoshita N, et al. Erythropoietin in patients with acute coronary syndrome and its cardioprotective action after percutaneous coronary intervention. Circ J. 2009; 73:1920–1926.

51. Duh MS, Weiner JR, White LA, Lefebvre P, Greenberg PE. Management of anaemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents. Pharmacoeconomics. 2008; 26:99–120.

52. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010; 116:4045–4059.

53. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007; 43:258–270.

54. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, Epoetin Alfa Study G. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001; 19:2865–2874.

55. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst. 2005; 97:489–498.

56. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006; 98:708–714.

57. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009; 373:1532–1542.

58. Mercadal L, Metzger M, Casadevall N, Haymann JP, Karras A, Boffa JJ, et al. Timing and determinants of erythropoietin deficiency in chronic kidney disease. Clin J Am Soc Nephrol. 2012; 7:35–42.

59. Group KDIGOKAW. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012; 2:279–335.

60. Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2014; CD010590.

61. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361:2019–2032.

62. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010; 153:23–33.

63. MacGinley RJ, Walker RG. International treatment guidelines for anaemia in chronic kidney disease - what has changed? Med J Aust. 2013; 199:84–85.

64. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis. 2008; 52:897–906.

65. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S, United States. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005; 68:2846–2856.